[
  {
    "ts": null,
    "headline": "Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip",
    "summary": "Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment.  Its first approved indication could come as early as next month in treating acute pain.  It will seek label expansions thereafter, including in targeting painful lumbosacral radiculopathy (LSR, a condition that results from a pinched or inflamed nerve in the lower back).",
    "url": "https://finnhub.io/api/news?id=397d55ec2401b6070b8dc58d0893551351b1f2b0640a5ef821341d9e313528bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735390800,
      "headline": "Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip",
      "id": 132186378,
      "image": "https://g.foolcdn.com/editorial/images/801957/physician-giving-medicine-to-elderly-patient.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment.  Its first approved indication could come as early as next month in treating acute pain.  It will seek label expansions thereafter, including in targeting painful lumbosacral radiculopathy (LSR, a condition that results from a pinched or inflamed nerve in the lower back).",
      "url": "https://finnhub.io/api/news?id=397d55ec2401b6070b8dc58d0893551351b1f2b0640a5ef821341d9e313528bf"
    }
  }
]